Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the FDA has ...

Key Insights Alvotech's significant private equity firms ownership suggests that the key decisions are influenced ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the U.S. FDA has ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

Alvotech (ALVO) closed the last trading session at $11.80, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...

Alvotech, a biotech company focused on developing biosimilar medicines, announced its inclusion in the Nasdaq Biotechnology Index (NBI) as part of the index's annual reconstitution, effective ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alvotech (ALVO) been one of those stocks this year? By taking a look at the ...

Alvotech (ALVO) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's ...